Free Trial

Alkermes (ALKS) Stock Price, News & Analysis

+0.23 (+0.95%)
(As of 05/20/2024 ET)
Today's Range
50-Day Range
52-Week Range
1.61 million shs
Average Volume
1.84 million shs
Market Capitalization
$4.13 billion
P/E Ratio
Dividend Yield
Price Target

Alkermes MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
45.1% Upside
$35.38 Price Target
Short Interest
7.62% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
1.36mentions of Alkermes in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$292,718 Sold Last Quarter
Proj. Earnings Growth
From $2.27 to $2.12 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.55 out of 5 stars

Medical Sector

39th out of 918 stocks

Pharmaceutical Preparations Industry

15th out of 417 stocks

ALKS stock logo

About Alkermes Stock (NASDAQ:ALKS)

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

ALKS Stock Price History

ALKS Stock News Headlines

Stifel Nicolaus Reaffirms Their Hold Rating on Alkermes (ALKS)
7 Analysts Assess Alkermes: What You Need To Know
Alkermes plc Q1 Earnings Summary
Breaking Down Alkermes: 5 Analysts Share Their Views
See More Headlines
Receive ALKS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
10 Analysts


Net Income
$355.76 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.66 billion
Cash Flow
$2.29 per share
Book Value
$7.21 per share


Free Float
Market Cap
$4.13 billion

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

ALKS Stock Analysis - Frequently Asked Questions

Should I buy or sell Alkermes stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALKS shares.
View ALKS analyst ratings
or view top-rated stocks.

What is Alkermes' stock price target for 2024?

10 analysts have issued 12-month price targets for Alkermes' shares. Their ALKS share price targets range from $25.00 to $50.00. On average, they predict the company's stock price to reach $35.38 in the next year. This suggests a possible upside of 45.1% from the stock's current price.
View analysts price targets for ALKS
or view top-rated stocks among Wall Street analysts.

How have ALKS shares performed in 2024?

Alkermes' stock was trading at $27.74 at the beginning of the year. Since then, ALKS stock has decreased by 12.1% and is now trading at $24.38.
View the best growth stocks for 2024 here

When is Alkermes' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 24th 2024.
View our ALKS earnings forecast

How were Alkermes' earnings last quarter?

Alkermes plc (NASDAQ:ALKS) released its quarterly earnings results on Wednesday, May, 1st. The company reported $0.43 EPS for the quarter, missing the consensus estimate of $0.58 by $0.15. The company had revenue of $350.37 million for the quarter, compared to analyst estimates of $360.26 million. Alkermes had a net margin of 25.17% and a trailing twelve-month return on equity of 20.31%. The business's quarterly revenue was up 21.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.10) earnings per share.

How will Alkermes' stock buyback program work?

Alkermes declared that its board has initiated a share buyback plan on Thursday, February 15th 2024, which authorizes the company to buyback $400,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to repurchase up to 8.2% of its stock through open market purchases. Stock buyback plans are often a sign that the company's board of directors believes its stock is undervalued.

What guidance has Alkermes issued on next quarter's earnings?

Alkermes issued an update on its FY 2024 earnings guidance on Wednesday, May, 1st. The company provided earnings per share guidance of 2.800-2.800 for the period, compared to the consensus earnings per share estimate of 2.740. The company issued revenue guidance of $1.5 billion-$1.6 billion, compared to the consensus revenue estimate of $1.5 billion.

What is Richard F. Pops' approval rating as Alkermes' CEO?

119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Richard F. Pops has an approval rating of 84% among the company's employees.

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA).

Who are Alkermes' major shareholders?

Alkermes' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.91%), Price T Rowe Associates Inc. MD (4.92%), Westfield Capital Management Co. LP (0.76%), Jacobs Levy Equity Management Inc. (0.74%), Jupiter Asset Management Ltd. (0.60%) and Principal Financial Group Inc. (0.58%). Insiders that own company stock include Blair Curtis Jackson, Cato T Laurencin, Christian Todd Nichols, Craig C Hopkinson, Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Michael J Landine, Nancy Wysenski, Richard F Pops, Shane Cooke and Wendy L Dixon.
View institutional ownership trends

How do I buy shares of Alkermes?

Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Alkermes have any subsidiaries?
The following companies are subsidiares of Alkermes: Rodin Therapeutics.
Read More
This page (NASDAQ:ALKS) was last updated on 5/21/2024 by Staff

From Our Partners